Nkarta, Inc. NKTX
1.12 USD -0.03 (-2.61%)
Regular-session close
1.13 +0.01 +0.89%
After hours · Nov 19, 5:00 PM ET
1.12 Day range 1.21
1.11 52-week range 3.72
- YTD
- -39.46%
- 1 year
- -37.43%
News
benzinga.com Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications Nkarta (NKTX) reports positive Phase 1/2 safety data for NKX019 cell therapy with zero severe immune toxicities across 5 autoimmune diseases.benzinga.com Nkarta Announces Integrated Safety Results From 40 Patients Treated With NKX019, Allogeneic, Off-The-Shelf, CD19-Directed CAR NK Cell Therapy Candidate In Ongoing Ntrust Clinical Trial Program No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS),…
benzinga.com Nkarta Reports Initial Clinical Data For NKX019 Demonstrating Early Efficacy And Favorable Tolerability In Autoimmune Disease Trial In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…benzinga.com Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026 Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast…
benzinga.com Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 55.17 percent decrease over losses of $(0.29) per…
benzinga.com HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12 HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.
